Plus Therapeutics Inc Forecast, price target & analysts
Plus Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Plus Therapeutics Inc Classifications & Recommendation:
Plus Therapeutics Inc Price Target
| Target Price | $5.61 |
| Price | $0.32 |
| Potential |
1,680.39%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Plus Therapeutics Inc 2026 .
The average Plus Therapeutics Inc target price is $5.61.
This is
1,680.39%
register free of charge
$21.00
6,564.55%
register free of charge
$4.04
1,182.13%
register free of charge
|
|
| A rating was issued by 10 analysts: 8 Analysts recommend Plus Therapeutics Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Plus Therapeutics Inc stock has an average upside potential 2026 of
1,680.39%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 5.82 | 6.60 |
| 18.53% | 13.33% | |
| EBITDA Margin | -240.03% | -213.40% |
| 7.13% | 11.10% | |
| Net Margin | -223.02% | -154.23% |
| 17.79% | 30.85% |
5 Analysts have issued a sales forecast Plus Therapeutics Inc 2025 . The average Plus Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Plus Therapeutics Inc EBITDA forecast 2025. The average Plus Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Plus Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Plus Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.95 | -0.60 |
| 54.01% | 69.23% | |
| P/E | negative | |
| EV/Sales | 0.94 |
6 Analysts have issued a Plus Therapeutics Inc forecast for earnings per share. The average Plus Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Plus Therapeutics Inc...
Current Plus Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 27 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Jun 25 2025 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Jun 05 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | May 05 2025 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Apr 21 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 27 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Jun 25 2025 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Jun 05 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
May 05 2025 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Apr 21 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Mar 28 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 28 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
